<SEC-DOCUMENT>0001193125-14-419937.txt : 20141120
<SEC-HEADER>0001193125-14-419937.hdr.sgml : 20141120
<ACCEPTANCE-DATETIME>20141120161536
ACCESSION NUMBER:		0001193125-14-419937
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141120
FILED AS OF DATE:		20141120
DATE AS OF CHANGE:		20141120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DBV Technologies S.A.
		CENTRAL INDEX KEY:			0001613780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36697
		FILM NUMBER:		141239235

	BUSINESS ADDRESS:	
		STREET 1:		GREEN SQUARE - BATIMENT D
		STREET 2:		80/84 RUE DES MEUNIERS
		CITY:			BAGNEUX
		STATE:			I0
		ZIP:			92220
		BUSINESS PHONE:		33(0)155427878

	MAIL ADDRESS:	
		STREET 1:		GREEN SQUARE - BATIMENT D
		STREET 2:		80/84 RUE DES MEUNIERS
		CITY:			BAGNEUX
		STATE:			I0
		ZIP:			92220
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d824671d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the Month of November 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-36697 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DBV
TECHNOLOGIES S.A. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Green Square-B&acirc;timent D </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>80/84 rue des Meuniers </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>92220 Bagneux France </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form&nbsp;20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation
S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated November 20, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><B>DBV TECHNOLOGIES S.A.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;20, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Schilansky</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">David Schilansky</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d824671dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g824671ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DBV Technologies Initiates Phase I/II Clinical Trial </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>with Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk for the Treatment of Children with Cow&#146;s Milk Allergy
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BAGNEUX, France, November&nbsp;20, 2014 </B>- DBV Technologies, (Euronext: DBV &#150; ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a
clinical-stage specialty biopharmaceutical company, announced today it has begun enrolling cow&#146;s milk-allergic subjects in a Phase I/II clinical study to evaluate the safety and efficacy of
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk, an epicutanous patch for the treatment of children with IgE-mediated cow&#146;s milk allergy (CMA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B>Pierre-Henri Benhamou</B><I></I>, M.D., Chairman and CEO of DBV Technologies said: <I>&#147;Milk allergy is a life-threatening condition for which
there are no approved treatments. As part of our commitment to improve the quality of life of food allergic patients, we have continued to advance our pipeline, and the initiation of this trial marks an important milestone for our patients, their
caretakers and our Company. We believe Viaskin has the potential to reshape the future of food allergies immunotherapy.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Viaskin
<B>MIL</B>k<B> E</B>fficacy and <B>S</B>afety Phase I/II study, or MILES study, is a multi-center, double-blind, placebo-controlled, randomized study designed to evaluate the safety and efficacy of
Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk used to treat subjects on a daily basis by Epicutaneous Immunotherapy (EPIT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Eligible subjects are those with elevated
cow&#146;s milk-specific Immunoglobulin E levels and who show clear objective signs or symptoms to an eliciting dose of cow&#146;s milk proteins <FONT STYLE="FONT-FAMILY:SYMBOL">&#163;</FONT>300 mg (approximately 9.4 mL of cow&#146;s milk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The MILES study is composed of 2 parts. Part A, or Phase I, will evaluate the safety of three escalating doses of Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk (150 &micro;g, 300 &micro;g and 500 &micro;g cow&#146;s milk protein) versus placebo over three weeks. Part B, or Phase II, will evaluate the efficacy and safety of up to 12 months of EPIT
with two selected doses of Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk from Part A. Approximately 150 subjects (18 subjects in Part A and 132 subjects in Part B) from 2 to 17 years of age will be randomized in the study,
at selected North American sites, specialized in the management of food allergic subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The primary efficacy endpoint is the percentage of treatment
responders after 12 months of EPIT. Responders are subjects who meet one of the following criteria: a <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 10-fold increase in the cumulative reactive dose (CRD) of cow&#146;s milk proteins at the Month 12
food challenge as compared to the baseline value and reaching at least 144 mg of cow&#146;s milk proteins (approximately 4.5 mL of milk); or a CRD of cow&#146;s milk proteins <FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT> 1444 mg (approximately 45
mL of milk) at the Month 12 food challenge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bpifrance will be providing &#128;3&nbsp;million in the form of an interest free loan (PTZI: Pr&ecirc;t
&agrave; Taux Zero pour l&#146;innovation) to DBV for the clinical development of Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk. This funding demonstrates Bpifrance&#146;s continued support for DBVs development programs. The
interest-free loan provided by Bpifrance has a first date of payment as of June&nbsp;30, 2017. After this initial payment, 19 linear quarterly payments will follow until March&nbsp;31, 2022. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g824671ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Viaskin Milk for the treatment of pediatric CMA is DBV&#146;s second most advanced product
in development. CMA is the first allergy to appear during early childhood and the most common food allergy in infants and young children, affecting 2% to 3% of the general population. CMA is often missed in the primary care setting and can be a
significant cause of infant distress when left undiagnosed. Symptoms can include gastrointestinal problems including vomiting and diarrhea, skin rash, angioedema or rapid swelling of the skin, and anaphylaxis. The only option available for CMA
management is the avoidance of cow&#146;s milk, which can lead to issues of dietary imbalance, failure to thrive and poor quality of life. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About DBV
Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies is developing Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, an innovative new approach to the
treatment of allergies &#150; a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact
skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are
currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut and Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk. The
clinical development program for Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Peanut has received Fast Track designation from the US Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on DBV Technologies, please visit our
website: <U>www.dbv-technologies.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Bpifrance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Formed by the law of the 31st&nbsp;December 2012, Bpifrance (a public sector investment bank) is the outcome of the merger between OSEO, the FSI, CDC
Entreprises and FSI R&eacute;gions. Its two shareholders are the French state and the Caisse des D&eacute;p&ocirc;ts bank. Bpifrance finances businesses from the seed phase to transfer to stock exchange listing, through loans, guarantees and equity.
Bpifrance also provides enhanced support and backing for innovation, export, and external growth. With its 42 regional offices, it is a one-stop shop for entrepreneurs in each region for all their finance and investment needs. Bpifrance also
participates in the management of several European funding programs. <U>www.bpifrance.fr</U> - Follow us on Twitter: @bpifrance </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking
Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements, including statements about the safety and efficacy of DBV Technologies&#146;
product, our ability to successfully complete the clinical trial, our ability to obtain regulatory approval for and commercialize Viaskin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk, and our ability to obtain funding from
Bpifrance. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include
uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, the risk that historical clinical trial results may not be predictive of future trial results, whether Viaskin<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> Milk will be successfully marketed if approved, and subsequent changes in the agreement with Bpifrance. A further list and description of these risks, uncertainties and other risks can be found
in the Company&#146;s regulatory filings with the French Autorit&eacute; des March&eacute;s Financiers, the Company&#146;s Securities and Exchange Commission filings and reports, including in the Company&#146;s prospectus filed with the SEC on
October&nbsp;22, 2014 and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. DBV Technologies
undertakes no obligation to update or revise the information contained in this Press Release, whether as a result of new information, future events or circumstances or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g824671ex99_1logo.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DBV Technologies Contacts </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>David Schilansky</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.&nbsp;: +33(0)1 55
42 78 75</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>david.schilansky@dbv-technologies.com</U></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Susanna Mesa</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><B>Nathalie Donne</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">VP Finance, US Investor Relations&nbsp;&amp; Strategy</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.&nbsp;: +1&nbsp;917-346-3447</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>susanna.mesa@dbv-technologies.com</U></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director, Corporate Communication &amp; Business Development</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel.&nbsp;: +33(0)1 55 42 78 72</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>nathalie.donne@dbv-technologies.com</U></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>DBV IR and Media Contacts</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Todd James</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><B>Rooney &amp; Associates</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Investor Relations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Trout Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel. : +1&nbsp;646-378-2926</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>tjames@troutgroup.com</U></P></TD>

<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media Relations</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marion Janic</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel. : +1-212-223-4017</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><U>mjanic@rooneyco.com</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g824671ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g824671ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`<`)L`P$1``(1`0,1`?_$`+$``0`"`@(#`0``````
M```````("08'`04#!`H"`0$``@,!`0```````````````0(#!`4&!Q````8"
M`0,"`@<&`P4%"0$``0(#!`4&``<1(1((,1,B%$$5U5>7"1E187$R(Q:!D1?P
MH;%"),'A4F(8T?%R,T,T)35'"A$``@$#`P,#`@,'`P4!``````$"$0,$(3$2
M06$%43(3<2*!0B.1H=$S%!4&L<%2\.'Q8G(D_]H`#`,!``(1`Q$`/P#[^,`8
M`P!@#`&`,`8`P#$+7L"BT1L9Y=+C6*HU*05/>L,[&Q`&(`&$13*^<HG5_E]"
M@(C@&MZ[Y0^.=M?_`%77-W:RE9'J`-&]PA2K'$.>2IE6=I`H;IZ%$1Q1@WDB
MNBY237;JI+H*E`Z2R*A%4E"#Z'343$Q#E'Z!`>,`\N`,`8`P!@#`&`,`8`P!
M@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!@.Q]I:]U%675RV7;8:F5IF8A%92:=
M`B0ZRBA$DVS1NF55X_=J'.`%10344-ST+DT;=%J16FK(5/O..Y7L5C>-?CE=
M-H0'Q(MMBW:6::HI"[D.0]UBC8VQK%+L4P,0_>1NB!RFZ#SFQ;Q;US9:&&>1
M:AU(L)>7/G/8MFWW6AU_'W7\Y0?[94ED/[<M%K:`G;(9O/1R#:1)82_-J-6;
MD"+*=B9#*@;M#@,VEXV[U1@>;;Z/4T_X@_F3>:GE$]V,2FT[2L\IJNY351GX
M6QMY6I.YD\'/3,$N\A9=E/O635-VI"J*)@X2,8I#`!@$><2\;<6R"SK:?W;%
MAS#SP>4A9-#R:T3>](1RAB($O<6Y1VGKTS@3%`XO)BHLSR4.@!.X_>NT$H$+
MU$,U+F+>M[QT,\,FS/2+U)OTF]T[9%<CK?0[)$6RLRR(+1\U"/4GK)<H@41(
M)TQ[D'"?>'>DH!5"#T,4!Z9KZ]=S/HU5&6X`P!@#`&`,`UYLS;&N--UEQ<-G
MW"%IE<;"4AI"7<B0RZQU$TB-F#)`BS^2=&.J4`2;I*J=>>..N`1')Y>[7V=[
MBWC+XNW;8E;6(<L;LO8LW':AI3Y0GP*+Q[&QHC:95FDJ`AW$;(^YV_"/4!RU
M%U9%7Z'X9QGYE5B0!Z_MGBOK@ZIC"$(C5KU<%VQ!ZD(K(C.MFRYB@/!C%`H"
M(<@``.2_CZ$?<<.B_F45$47B*_B_M]N50!=0K5A<M>2BJ`<\E:R;V5?QR"Q^
M>@G(H4..H=<G]/N/N/8+YKS&N'"3;RFT#L'0<>JHFU2OC)RUVIK91X<P?`XL
M-);N7D0F)3=W>Y:E('`\FZ<Y5I=&B:OT)HT^YU38%>CK92;#$6FMRR!',=-0
MCY!^P=)*$*H'8N@8P%4*4X=Q#`4Y!'@P`.5^I/T,FP!@#`&`,`8`P"(>W/-O
M1NJ)YS14Y65V)M)(I"H:TUO$N[18C.5DP4;MY!TT3^HX3O*8!,+MTD)"\B)>
MG&9(6IW']JT*3N0MJLG0C38?+#S)M!"JT306O=3Q?88ZLAMJ[?W5-`EQR!_[
M?J"L85HJ4`$1(=97-VWXZ])5:T-*YY&Q"M'4IY\K/SSO);Q.O*5.M#+6]S>G
M3*JI_:M.7;MD0,*H>WS+VA!RH(>T/H(=,S/Q5Q=3`O*VFZ4/WIW_`/U`T!P"
M26Z=<-F1#G(0SZ+9V*K%:\@8#"HJHE=8MT//'45FA/HYZ],%SQU^.L55&>'D
MK#='HR^OQC_,;\4O*]C!FUGLB,)/SK9-=G6)I5-D]<J&(!E&T9(E,I"3"R8^
MA&[@RQ@_Y`],T[EF[:TG&C-RW=MW56#JB=68S(,`8`P!@#`&`,`8`P!@#`&`
M,`8`P#P.G39BV</'CA!HS:(JN73ITLFW;-FR!!47<.%U3$21112*)C&,(%*4
M!$1XP"KF5WSOOS'ND]KSQ+?!K#2%<E?JJW^4KQB:0>V%5J4R4E$ZIC'K8C)V
M!E%?@>$4]SA,JONMRG`JEZ*.^H-7V_2GY:WCJLLX\C[J3=VV'KM5>;D+_8YW
M8=_DI)<RBBYUZ55'"Z4:@*J9NWWVO(";@RAA'G(UK5*@,52OWY/%M<MH*;U1
M!T]!X8K=O+V'5EYH\<03]"'/8F2#3Y(G(!_5453*'(<CUR:RWJ0;@CO&.WZN
MB5-I_EW>0!YFK`Z1EO\`0JPV=E?=1VQND5$TE$PMB.X?O("4>((]B9CJ&6*<
MXE^81``X<D]'^TDEOXM>54!Y&0LQ%R4"]UQN*BN!B]F:FL)CH3];D41325D&
M3=VDT?/ZXZ<'[4G)D2"13^DH`&[1/5J@)89`&`,`8`P!@#`&`,`8`P!@#`&`
M,`8`P!@#`&`,`8`P!@#`(F>2ODZCID8&CT6M&V=O6]&41H^MV+L$B(H)B3YJ
MSW9X@"J]:J3%(3&^84(4'!R"F00X4.GDMVW<E1%)SC"-6T1DJ7C?]<V)KM/R
M0L7^N>X"F3<,'<TV(2B:^^,RP1&OJ@F)8ALV:*"3_JUT3KJJI^Z':8P\]JQB
M0M)2?N.5<R;DW2NA*4WQ%`HCP!2]I`#T*`="E*4.`*4H>@!T#-W3CQ6AK5DG
M5;E1WG'KG=NG)6W>4/CZ^F[-*VQQ6(:_:S84ZO6-XY-'1,=5:G+P3J0.@\3;
MH.4B`[2^/O,L40$I`^&M/5LAZ[T-"_DG>-?D+KNM;,WKN=?^R8[=MNL-AK>I
MUZXV9SB;-S/3CMU:+&\646>PRLG+O5U6;%,ZA!:F(<1(!BER=.XIZ%]1RD4(
MHBH0JB*Y#)+(*E(JBLD<!*=)9)0HIJIF*/`E,`@(>N1Q@_<JH*I%&=\?IS6M
M@>[1\29ACJN]+&*[L6O%2<ZDVN*2YUQC++#J*"C6WRXK*`228@D=,3>A>1.&
MED8D)KE!49N6<EQ=)>TF%XV>2,%O^O2*+B(=47:%-=#$[)U=-JB6?J<H4YR(
MNDR+HM5Y&N2Y2>ZQ>E3!-4@\?S%'.-.#A*C.I&2DJHDK].4+'.`,`8!$SR(\
MDG^LY6NZLU/4TMJ>0=[+W5>@D=K-XR`AA.=):\[#D6B:IJ]3F*X`45%!2%P?
MDI#EX$P64:Z]"&Z&*:M\/XA"QL]N^1EE4\@-X`=)XQF[,R1+3M>&$%%%(37%
M13XB8YBS6<"4KM9([I84RJ?TS"(9.NT5HQ]=R;`+)AT`WIT]/]W``'ID<&2!
M73`.1$0#UZ@/T^GT?3A1D]A1GI*S,8B/:J];)B)@*`*+)$'N'G@O!C@//PC_
M`)9/QR6Y*3>QX1D(65279F69/V[A)5!RU4%!R@NBH42*HK)&[TU4E"")3%,`
ME$.@ACXY[I5(H^I!>X^)LQJR9>;3\+I=MK"V@?ZSLFEU.$],;@5;J&7&.EHM
M93V:7,/41%!&2C_9*B40`2%Y%0'_`-HBE-C>WCMY%US?=?DR_5KVE[*I;OZB
MV=J^?`6]DI=B;@*3HAVZQ4G+ZONW*:GR$@"94G:91$.#`8H1*-/H$ZDB\J2,
M`8`P#TY"081+![*2CUI&QL<U7?2$@_<)-&+%DU2,NZ=O'2YB(-FS=$ACG.<P
M%(4!$1``P"IO8&^-E^64Q,5K2UFG-3^.\2\=1$KMJ'3*A>=MOVHG:2<51_G$
M@-`4T@J<EEDA,JZ`OP\%,8@='#PW>?.>D3GY>8K/V1]YE.NM6T#5$0:$H%9C
MZZS5$%'BS4JBTC*.?_J/)>5=*+2$BZ4-R(F54,`"(]H`'3.["U;A[%0XDKMV
MY[W5&&;_`-D0NK]=V.S3+]!DW81+]V=1=<B10*BV65'D3F`.1`!S(8U%1V/A
M.VM:)'S'\C++8V?OK5Y&178L'!0,JW42;NU2@)5@`J?)RJ!Z#SQD47<:]C;%
M\\5HY'6L@XCV8'DHU(IS<(CWB'<3G@.1YY_WXV5%L*:\M.1!74KFW:?V9!SM
M4G96MM9269,YQLR5.FP?`5RE[19%D?O:KG3./)#F+[B8CR4Q1ZYCG9MW(M26
MIDA<NVY5B]#[=_!/\T&RTH:MKSR.F7%FU_-(M$('8[Q4SJ;IIE$6J#5I++=@
MJS58;@01.HH*CYH4W?WJIE["\/+P967SCK$[>+FJ[]L_<?1XR>LY)FTD8]TV
M?,'[9!XQ?,UTW3-XS=)$7;.FKE$QT7#9PB<IR'((E,40$!$!SG'0/:P!@#`&
M`,`8`P!@#`&`,`8`P!@%;OG9/VO95FU!X6T&3^II+R`<RDOL>>0,L5]7=2TY
M1M(30MC(G#L-8U&RK4!,4Q#@F9,0X4-EH^KV!BFW+388^PT7\O+PR.UI4G$5
M1DOLZ^L3@H;3>LA!)-T=!=(Z:Z=^L)9)-T1QU6,JZ(<!*HM[J1?\GJ"3VAO"
M_0?C^Q24K5.96.XJ.%)"5V5>&S&RWV7E7)BJNWZDZ\:F68^^X`5`3;@D4IC"
M(]QA$PG)O<$CK-4JM=(I:#M]:@+3#.`X7B;%$,)J-5#Z.]E(MW#<PAQT'MY`
M>H94%8&WO&BR^'\C+^2OALG(,8J-<%F=P^.X.U5:%;:<V33&>EJM$`J@$388
M9@W.LD4IS]A1.*(!P*"LJFW4&/\`D5+0TQ4]4_F>^.:RCB7I,;".-E0S9V5L
M:ZZD=*F96>JV9M'BH5Q9*B[=^TI[ISD0(@)@[OET<M%_E9!;'5[%&6^M5ZV0
MJP.(>SP<38(EP'`^]&S+!O(LE>@B'QMG)1Z".4).]P!@#`&`,`8`P!@#`&`,
M`8`P!@#`&`,`8`P!@#`&`,`TWO[<<'H;5%MV9-E!V:#8'3@8,B@$>6FU/2F;
MURL1J8#[KA],RAB)%*F!C@03'XX*.3%.4E%=2)/BN3V1"GQ^U9.U\E@W!M-R
M>:WON/V)R]R3@RJB=8BG)Q?PVM8!-P912/@JFW7*W%(INTZJ0<]"$X[^+9A;
M@G^8XN3<=V;2V)(B/(\YM-M_0PK2-.HR`8[;FL8\J]@;S*OR\6K$/OK!SW@D
M+9L5$ZBCD%A*8$C-^WO`W`]HASQTP#MF"*"#-HDV``02:MD4..!_H)(D(CP(
M>H>V4,`]S`.`$/VAS_A@43W(K;\I%EJLY$>46F&`J;FU>T,67A4$_P#IMJZW
M-[:5CJ%@11,BM(NHN)*HYBSBH4R"R73N$"`&EDXT9Q;AN;./?E;=):HL3U7L
MJL;AUU3=G4UPHZK5V@F4Y%G6`A7")')!*X8/"$.H1-_&/$U&S@@&,!%DC``B
M`<YQ&FG1[G73355LS8&02,`TEY"[HB-"ZJLFP9%$TA)-R(0U/KZ29U75KO4Z
M86%2K#-%,Q%%%I>64(0W`E[$@.?D`+A)MT1#T1J;Q:TA+ZYAYG9NU'*5A\A]
MP*)63:-C6(512#^<(BX8ZRKRIC+*,*C32@""39-0R0K%,8!$H$XSQ@VJ]$0G
MH2N.IR(<CR`<C^P`^D1Z^O(YD4'2I5RU['72<HUBV+J2=K%;M&*"KEPJ?D2)
M)(D,<QC"'/``!>N))0BY2:XHF*<Y<8E=>UO)^R+JKA7R.XR$*L*+11,YVSE]
MVB<H+.G1C`9FW,F'?P0.\``.1Y'C//Y7F9*?QV.*6QZ'#\1SM_)=K]"+C[=L
MD[?/45)!DY<@":QA76<*BB*1A!10PJ*F.N(G.`CR/\IA']F<V6;?;]W0Z4?'
M65&L5H9W0MH6(SD'+1T9EV"FHFHW<.&ZI>XQB#[@>[[#A--<!`0$.!*(>@Y:
MQFY*GR4G0Q7\/'>E-2?VI=SNY]1*"MJ2+:2,;VH^0;IF!K(B4"E]I0WN'*1T
M/41`.@_1G>PLJ.3'A<]YP,W%=F7.'M-5>5>N;;5)>,\MM$QW?MW6C`4KS5V2
M:WM[JU44"%EJI--VRK<9&5KS8#/HM50W*1T1`.1!,"[SC31['/Y=43(UUL"K
M;4HU7V)2I)*7JUOB&LS#/T1^%5LX`0.DH'JFY:."'16(/4BJ9BCU#,!D,TP!
M@#`*L?+R^S&\=GM_%*F2ZC37M>:,+-Y)3\2NY1=+-G2@*P6GBO4#@B@K9V!A
M=/TS%/W-1(')0`Y3;N%C_/=U]J-+-R'9MTC[V9K$14=#1L?#Q+%M&Q46S;Q\
M9',TR(M&+%HD5)LU;)$^!-%%(H%*`?LST4(QC%1CL>?;<GREK([8A"E*`<?\
M.`Y_9QSSR`Y<CZE;?D'K*-\IM_570=P=28:KA:S-[.V-$Q#LS%Q;HJLR$7'Q
MM(=.R@8S>'L\K*D2?B0"JF9D4*0Y3&`0`D=$:GU-3ZV2F5W3&G86CQY`;MZ3
M$:XJT9744B%!(2HD;1R;WYCVB@7YDRIES<=QC".`5:>4_CG$:ZV'+PE1:+FJ
M=@AV,_%,70@NJT:2J(G<1W>!"BLBP>`H1,1`3`EV\B(@(X!07NK0;N`MTA'(
MLU4&TBN9]%+=@@"+I(Q#I@4X%*''>/3^&`31\;Y*-O\`K]2A6-P>/M]<$42=
MZ@I.2*-BIIHND3&$3APIU`Q?3*RBIQ<9;$?<I*<'22/HH_*@\K+`B_6\4-K2
MAE7C!LX=ZC?NA<**KMF2;Y_+U;YIPJH4S5..2!VP2`I`0*FNB`B4$BAYW-QG
M8G5>UGHL/)^>%'[T7OYHFZ,`8`P!@#`&`,`8`P!@#`&`,`K9U$R;6W\R'RPM
MDH47#C5^M-0T>L"N8YRQ32SPQIR=.T)R!$Q?.F8]X\"(@.3^7\0>K^6\V3O$
M7Y">2,FU2&Q;NWI;U6[E0I5'3*H5@[>-@X5-P8/<3:M%C+%[``H&]L@B`]I>
M)E14IZ`LPRH&`>)=!%RBJW<))KH+I*(K(JD*HFJBJ04U4E"&`2G34(80,`]!
M`<`JA\0:9!*LO/SQ&60]NC5_:UVCJ_'@`F3C*GLVMF`C!L8QA.4D=[913Y,(
M@?DW0<N]&F#>?Y:=ED[)X<:M++.%'3NLJVVED74'N.+&JVV:B8M'G@!$C2-0
M21+Z_"F'7(DJ,$\,J!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`K.
M\B7#C;WE]J?4"SCNHVC:HCY!6R/!(JB4G>7DH[K>OH]Z<1*()QB0KO0(/<4_
M<')>@#F[A6ODN=JFIE7.,>*T9(D1Y$1'J(CR(CZB(^HC^_.ZU1T6QR>FNYQD
M`8!I[?MM94K3FQK`^,D"3*HS1_ZW/M%`6ATSJ*@'JF0J@\A]/ID@V9!O49"'
MCG2(=I%6;41)R/P'!$H*$_?VG`?\/XX!VN0!@`>WJ!N!*("`@(<E$!Z"`@/0
M0$.@@/K@AUZ;FCO#IV.KMR>0'C>LJ+6O#(,=X:?BA,)F[.F7,P,;?$QH")OE
MV4%<DN"H\@`"Y,8I0`1'.#F6U"Z=G%FYV]=T6-9J&R,`KNV2];[M\W*+JYV8
M7]!\::@GN6U1QDU",E]N3CENPUNB[6*!!<'@H=ZI($2Y.D8RH]Q>2]-FS!R3
M9BN2X_0G.#GN^(IR_P`>.>O'(B'4,V4DE1F*-U-TUU.`7/SP)B_P]L`_[<A\
M4JLS\(R54:-WM*&+$PU>`ZI?KMZ=50J8B7W$6`$5,14Y1#E(5%`$2^AN./3.
M1Y>ZX048]3H^)M*[>;?1E?>S8B;D@28QT:DZ(10SM<41*@;Y<"F323#GX%%C
MN.T`XXXY$1],\A=<E)\$N1[>S:^W=T1#EC3IUJ\6D)B%=*N3DF&KA@W,;DBR
MQP(0"\'`3]Q2=!+Z=W3-.*NZN>YM.U&2HJ4.K(X\@HU%JRB-0NVD>*_MDG75
MIA4%4$5S\`<[$ZAGCA)0O'<`DZ#U]1R/ER+<*1BZF)XL'+DZ4)`TEYLFOLFD
MM/RB1'D<NBLHU;]Q#$*D("4P#[@^X8@=.X`$!`,S8N1?C]\GHCGY>-:FJ4J7
M4:YG366EUN;<"FN,E%-E%>2_"H?V@36*8!``,`F`0,`AP.?0+%UWL6-R6\D>
M&O0X7G"/0B=XE*I:CW)Y$>)Y77;6J7*Q&V-0,%Q,9PWH6S"KRD_$H+'$QW+.
MN6]51(G(\D*X`O'`!E9--]RBT="P/*EA@&%;(NT9K>@7._S"B2493JS-6-V*
MR@(D5+%,%W9&P'$!X4=K)%2('43'.`!R(\86HV*G/&B(DU-??ZCV@_O7W=\N
M\VY>70D[`&4M9A<L&+=/D00814**"2*8<%(`CP&>GQ+*MV4_S,\UF797;SI[
M4R2A`X^+GGUXZ!_#K^W-LU@LJ5%%54X@4$RB;KUY_A]'.0#Y^/)'\Q&(\2OS
M#]./VM8D-@L;]W:3N-0@U$OK]2+V'8H1FQE(5%9$R;V4AIEN@X3;"9/YE,%$
MP4((@;`+MS7'44[=Y"#<[`JU4FFA4I.4H4Q+LXR7C6KM-!VR%P]=O/J](KU@
M\26*B54S@A3\'(40$`(EE;'GUY5Z[_N:OPVOD#7Y6DQ<DREY:O$%S'"]=KM#
MEBV3PJ(IODV!6YA,H0QD@.H)2B/`Y)!2K>_(%CL=X,<[UY-1;Y!03(.W3-0A
M2*"`#P)O8*`%,(!^X,`Q:-27:2;>[5]NHPGXWM3D&0CV"^0)P<>"B($,?N]!
MXZY`)F4CR!C8R0I^QZW+E@]C4J=B9>',(@5<DDS=)]S94JI/:40=I`=$Y#E$
MHD.(#ZYJYEI7+#?YD;&).5N^G^5GVFZWO4-L^@4[8=>.*D+=*Y$V..$P&`Y&
M\JS2=`@H!BD,"K<R@IG`0`0,4>F>8>CH>E3JJHS7!(P!@#`&`,`CSOOR0JWC
MTA5U[/3-IW`MK6ED&1=8TAS=%&!HA-BJL>9(V=M?JY)R5^4$##W>Z)#@'';D
MI5(;H1R_4IU3]RGE;^!LG]K9;@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5
M/W*>5OX&R?VMC@_5"O9GY-^97JDO_P#$O+`0XY$2Z+E#`4/_`#"$MTR.+["I
MEM!_,7\7KO/)U>4M$]JJPN!3*TB]RUE_KHSPZJI42IMGTP/U293W#<<"X+CB
MR2<+5TV>MV[QFX0=M':"3EJZ;*IKMG+9PF55!PW72,=)=!9(X&(<HB4P#R`B
M&5!6Y2GHZV_,RW-7)ALHV8^1FH*/:Z:[.'#>1D]91XPU@9$,;@#KIMC++=H<
MF[2B/`!EJ?;7N#TOR\WK/6\]Y,>*T@\*E.ZDW19+#6H]X((2$EKBX)QSR'F6
MS8W:=9F58Y#*G*`E(=VF'/QEYF2T3[`LWR@&`>G(2#**8O9.2=(,8Z.:.7[]
MZY4*BV9LF:)W#ITX6.($20;H)F.<QA`"E`1'`*B/&'8T=!ZH\]O-55(R4%>-
MC;$LE(5?$.T^M:W2(0T=5A2][LY3F)9T5N40YY5`2AU#C+M/1=2"6/Y>U"D]
M=^(6GHJ;3%&6G(B0O+U$2F*9$+U,R%J9)J%,`&*J2-E$>\!]#\Y5UKKN2;JV
M[Y#Z5T1&?6>U]BUJG]Z!UV46_D$3V"5*4#]I(BOMA6F)$RIR=A121,3O$`$0
MQ1@B6G^9SI%X'O0FL/)JR,!ZI2D'I";<1ZY.@@HBHY?-%1(8!`0$2!ZY/%]@
M>S^I5JG[E/*W\#)3[6R>#]417ZC]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5
MOX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"
MO9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5
MOX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"
MO9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5
MOX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"
MO9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5
MOX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"
MO9@/S*=4C_\`Q7RM_`V3^ULCB^PJ:?\`%BXM]M7WRJW0BQFXY*X[?C(*'8V>
M--%V&*KM1IT4U91,G&JJ**QCI%P\.=5N)C>VH8>>N=K`@E:Y]6<K+E6="9/T
M?[?L^C-TT]?P&"0(@4!$?0`$1_@'4<`KX_,)G3_^E[;S5)02GG(-&M,2E'XC
M&D95@1P*?3DP_+$/Z?1@$K=7S@/J]7EQ.`H2T'%/DQYY*"JT>BH;M$`XX,(\
M8!MK`/&)AXZ\?0/H(!Q^X>@]V`<=3&'D0Y'UZ].GI](\Y((4[MVA%^/_`)6>
M.FWIF&M4]%2U"VQKJ7BZ5#&L%ED4UU8*9B4H^((LW4?&;2J@*&*4X&!/N$`'
MCC.9Y&,6E)=3?PI4Y1]&;R_4IU3]ROE;^!DI_P!LMG+X/U1T.2>P_4IU2/3_
M`$5\KO\`#1DIS_A_^6R'&BK5#E]3%?"FU,]GVCRTW2W9344EL+>[6.C&5DC3
MQ5@8PM*I,+&1S"7C5#K'8/&OS9RJHB8PI*")1ZAF_C+C'78U;KK+LB>9%A#@
M"F'MX'GC_(?H'US.Z-Z%%1ZO8[))3W"D`#B/'[>.[TX]./\`WYCE&NBZF2S1
M2=61JWJ9=2S5P@&,5!G".729B@(=ZCE]\NZ.;UZ$(FF'[N>OKGG_`"JYW(5V
M:_T/0^'2BG+=U_W([R]IC83W!5.DH)`$024.GW@'3H!1,4YN3`'0.N<'].$Z
M-59[&S6E363S8\5WN'!D6@F(8R@F$A!$3"8`#@QN1Z>HAT'IFO+26GMJ;2BJ
M4,6D-DQ[\1,=TB?M#N#@Y"AP!1X^(3=.[C]OH&8+LN*JW0LK4VDTGJ=<V=?7
M!?<4'N1.!DB]H^YWIG3,!N#%'X@,!_\`/,-N,Y.LO::M]*#XT+2/'-XHKJB!
M*=,Z(,WLVP1%0#![C9K*+I(+%$0`1(=/ISZ=,][XZ,_Z*VI:456?/LYTS;B7
M25/_`!ZD4_*38T+H#R^\<=RR4#:Y^/LFK]OZZG8RAP"ECM$DFT<5J>A1:PZ"
MS95\5D\.)U![^4D0$W4`S.XU3^IJU^XRW]2G5/W*^5OX&RGVME>#]437ZC]2
MG5/W*>5OX&R?VMC@_5"O9D8O,#S<I6Z-%3VIJSK??-6DM@V*A5LTO?M8O:K7
M4V+BZP3J0;*R[A^X2(Z>-&ATTD^T14,;@,R685N1K2E3%>EQMR:WH22CVC9@
MW;Q[1(B#1B@BR:HI_"1-LS3*@W2(4`Z%213*4`^@`SU25%0\PW74[THCVAT`
M.G3I^SGKU]><D@Q&ZRBD7`2"R20J'!LJ(%`!$>0*/3@`'KUP#XY=]DMU-_,$
M<>6%AI+&VU+1=;M5WC*[+IORM9>Y),SQM'CUG+0I%F3AQ8':9R'3'W2)I',0
M.0`0@A5JZ[&\M2WJQ[8A9W9M]*@%CV'8I2X3R#5-0&+)[,JE=_5L<FY.LNG&
M1B1RMFQ3G,<J"10,(CR(R2=I.[LGJ='R+:DT0DA\H4`%PN@J8%A#GT$"&_?P
M`!@&$U^\WFXPAK-8JNRCS.E>TS(K90JI"&,).?C(4P'X#T$,@&3-:NC:A39D
MYCGZG!DEBE[1`##P"2Q>O)`$W\0P#0UQTK:B68YEDS"NS4(JB[9@8`<"D8HD
M[RE*!3F^$!YZ#E94<7%[4)3:::Z'U(>%'GE2M:>-&M=?VC6F^K/,U)M-Q*\O
M0=7O;36U4!L,J^9-VTNA(-TU5F3)XFBJ3L`4S$[1YXY'R]V'ZCVW/3V9)VHM
M>A*G]2G5/W*>5OX&R?VMF/@_5&6O9C]2G5/W*>5OX&R?VMC@_5"O9C]2G5/W
M*>5OX&R?VMC@_5"O9C]2G5/W*>5OX&R?VMC@_5"O9C]2K5/W*^5OX&R?VMC@
M^Q'(DW_Z@:U_H1_Z@/[2V5_;/U+]>?VE_9SC_4OY?ZW^I_E?[-^9^8^L/>_J
M>U[G/L?'SE::T)KI4WQD$C`&`,`8!K;9.GM7;@AUX+9M!JMVCEVRK0"V"&9/
MG31%8IP,:-D%4A?Q:Y1.)BJ-U$SE-U`0'K@%:;U#:GY:TRI,,7-PW+X2R*Z2
M#^&<.%9Z_>/ZRAA`CYBNX*U;NJ.*JA42I=Y2`(E*;VE>%'%DJJGY@;<\L:E(
M;IUQJORL\89IK:MD:7?'OFN'M>42<M+Y4),4&=VJ)NTH*NC/H]JH4&ICIF*J
MFJB8H*'X`NL7N#4\\17REA:%YT^&4FRAM^4-C]2WO7DFZ00-<H1FD$A-ZFO*
M3$B:BU@!1%$D<X74226;&)P=+A$Z4K3[9;,&]-4_F*Z%MRKFL;6DUO'?:L(Y
M&,LVO=NG3KJS.21`I'8QLTZ%.+>L"N1$A#*G;KB`<BEV_$)P?35`WU:?+#QH
MI<:$K9-[:MCF9DQ52,%QAG[AP0`*81:L8UT[?.Q`I@Z))G'KE>+!`RX[?V;^
M86NKJ/QVB[10/'!>0,TVQY!3C9S"+W*`:+MB2E+UTU26.X6+/,W"A%3+$`3I
M<`L""8F(M=)1U>Y!U&RVE?\`(2ZT'\O?Q\2.ST'IT\"Y\D+-!/B)1J-?K"RK
M=KJ]-^@D8K^PR,JS*J],('$[X04,']!<<;+D]V"2/D?Y3N]<S<#XT>-5<8WW
MR.L4>C'P%8;`B>LZNA&S5H=*Q7G^NV(T8-(83*-FX&#X4@.KP3L(K51TY/8D
M]K07@O2J(Z4V/O)TAY`^0$[[+JS;$OB!+$PC'27?[3"D1<RV.G#1C-(2$3.8
MGO<I\D]D@@D4Y-Z=`3O33(D0B:1"IIIE*1-,A0(1,A"@4A"$*`%(0I0X``Z`
M&5!^\`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`QU[`JR\<A]B\>848<PF
M<,O+'8+M83#\8IS,9!OFAAYZB!T.H#].=O`_DT>YR<NGR4)29OM4U-09`.EG
M'9F[04R&[5'`^V'[?;$!]P0Z@/0`P"LWSP=?/T6$JQ#"(/907CE(!Z&(W3X3
M`0]!`3&Y_P`,`DGX^2)Y#5%-5[O^H81B;,YA'D0%FH=(H<^O\I.,`E<R<%=-
M45@'D3D#O#I_.'\P<`(],`]OT'_;T$`P!P'[OX?NR>C^@1$_:K)::\O?"&)9
ME$SEA8MI6MP!/YBQD/6XL'!S<<C[?QB`\\!TSF>0_EQ75(WL)5G)^K+6.O\`
MAG(.F<X!6MXKO3,[%Y;PQC#\U%>6VTEES&/\9T9=*(E6BIA$>X1407Z"/KQG
M:PXJ=NO8Y.3<<9TZU)C-W8J<"!AY$.O7GZ0_?T$<M<M\7IL5A*5*L[ULL)N@
MB'=QT_\`$/[0X^D?\LU[D*:U-B+U4B)&PYZ;-N8:Q8&WLQ#QDY3HJZ8*>U*L
MQKJ,O.I.2F,<A#Q[YB<I1+V]P=!#GXL\3F9-[^\O'O)_`U6'X;_0^A>+P\>7
MA+>38?\`^F#?R?5MTIZ]"E3\R38/D9J>5C7^FO&[:6Y8XS87TG*566BX6KQB
M)3NB?5K@_P`R,T^EO@*<0]LC8$S!R<3!VC%C"M9N3+Y;OQP]#HQR[N#B?+9M
M?+<V?K7L>OHB7NVY]._WP^H=\H[E$ABRD#;%$%73-RAVIO4D7K,RB;]H5<!!
M-3X1$/4`$!`-;*Q%;F[-J=;:ZFW8RG*DKT5&_+\KW*^-Q^1^Z8_:S>AT#Q=W
M#LZ);R!&TY86CQ>.C$^WV.YK"MF3E-8IFZ)SC[R_"1CAT`2]<R0\7CY6'*]<
MN\>/J^O8C)\GGXN7"S;QY2BUNEI0N+TV\*QH,9-RK&RUH?[?&?>5^[>T::JH
M)LA=.8R4%FHY1%:-*D83^VHJ7H/!ASSL*X]:3<Z>IER+<[]Q*6[I^_8LR\.K
M?.6;73QZYD7DM7"/V(5"6=$*FB_BW48C)+*QQ$T$`*R(L]*0"F*)P$H]QA-S
MGLO\3R,G+P[MS(;E;C<XQKZ=NQY;_+</'P,NQ;M-.[*WRG3H_P")^=PJ&?>:
M/@^P3'M69Q_D3.K>H"#(E&CH\QAX'D"J.%BD'Z.1XST5[BDZ'DT^4JK8GYFJ
M7&`5^_F5$,7QUB)#@10AMV:7E'G_`(2M4KQ'MSF/]':51R4>OT\9EL?SH_4P
MW_Y4OH=8D/*J@@(=5%!#CIZJ>@!^\/\`=GK3RYVI`$W8`!U$`]>G'3GD<`ZR
M>8I.XQVDJ)``Z(\>X)0#TZB'=QSS_#Z<`HJ\L--3C9%RTD*C(IUC8EIGYQ[/
MNF(`Q%&H,T(JKPH.P[RE/*+2SY^1(X`)TDB'X#C(!%77E6:P<<$&U1(5NDN*
M12=H`0H%X+V\`4O':!?V8!ON-H#)9#X&K<Q1`!.0R8!W#^TWP\#UP#QRM"9H
MH'542;IH()G-[*292E'CD?3M`!]/\\`TK`1AE;4HJU2.*#<YBB"8?24P<E`"
MAQZ<8!D4@BX3L;<SLABHN52E*"H#R!>.>G/3T'*N+=?2A#='3JSZ3_RM&:C7
MQ#K2Y@$$I*[[(?M0'T!L-MD&9.P/0"F.S,/3Z1'/+Y'\UGJ<=.-B*>]"Q3,!
MF&`,`8`P!P'KQU_;@#`&`,`8`P!@'JO&320:N&3YJV>LWB*C9VS>().6KINL
M42+(.6ZQ3I+HJD$0,4P"4P#P/3&P*H+AJK:/@);)[</CC"RVQO'&POC2NUO'
MMNX76E*6J<"HA:M;.7'UH^%L1T^56<M$40`B)0*IW(D(HWNJ2T?N!XD-6U/>
M4LKY=?E\;CC=>;2F&JZUWICYL"U5NSL`3%6&V'27"YE*E.NEFA2&<@W,FH8W
MS!/C/\P:*OVRV!TU_P#(J7`6]5\X/R^IZ553:E1<7JB5YAMRLJ)%[B?,1,@T
MCC2$-[ABJ&!%.0%=(H_$``/(N*>S!JJ&VU^7K3G8RVHO!S:=VN'?_P!)#*Z4
ML;XHK&YX$/[L=3<<T.7O'@Q4!$O'3@0#'%]=@2`=M_-ORKADJT%88>#F@'D6
ML29='>,9G;,U!&,DFXAFD:W2A!HZ*[(51.<Q&9TR<\B<H]HSHGHZ@PQILB&H
M38GA9^6_64+!<A,K_J#O!5<\K4->/5@*VFK78[&Y9O&-KM8I)<D3(<6R1Q(B
MW(H8"HD;NLP3L\7_`!5I'C-67[>,<N[9L.V+_6FR-G3HJ+6.YS2BRSI554ZZ
M[L[&+1<.3BBV(H(=>]0RB@B<:MUVV!*(``.@=`R`<X`P!@#`&`,`8`P!@#`&
M`,`8`P!@#`&`,`8`P!@#`*Q?E4]9>;VWZ7P5&*WU0*WNN%.JH!05M-65-1[4
MP;=P]ICG8(H.C%`0-QUX$.N=3Q]S5PZLYV;!Z26Q)+M$.>GH'(_PYXY#KR.=
M9Z.G4YYQP/\`L''T=?7(!@TRN*[U3IRFW`$0XY#J4>3CQ_'`*S/)]Q]?V@6P
M&Y29`#<@=1#O(81/P/0H#W#@$BO&!T(U$\48W_VJ@G3*'/':<3B/\.!+@$O8
M!02'7:&'GN_J)^GT@`"''7CD<`R@"AT`?W^@^HA_$.<`X$@=>O/'T>GK_CDI
M5!'O5S,=E>=4Y8F8^Y!>-^GAID@L8!$O^H&UI)"<.U0YX*)F=4C>%A#GL,<"
MB`".<7/G6?%'3PDE!OJ65YSS>&`5@09'.KO-S?\`0GJ)48C>5=JV\Z>Y!4`*
MX>P3!E2+DQ!(`$/F?GD_F#?$!@3(!NW@P#G7\9-:QD<GR$&FIQ);MUP+P)3'
M`P"'T]Q>?IYX].>,Z,H<WH:<)=692W=%`I5.1#GKP)N!$!]1XY_9FE*VY2<6
M;L)?:8E>VK.3;MG2*:2KV)3<K@N<2@*#55,2+%3,;X064Y```/B$HFX]1SS_
M`)2W%N$J+Y81:J>I\-?N6%.+;=N<DTO^MB$6U]A0L%"RH.X.'E_9064`)-DU
M>I)&3(<2F`KENNGW%`.@<=><\?DW':G5*K?>A]-P<&,XQDI4@UJO^_\`N0^M
M_D3<J=`HLWM$<JLIR(4^3GHQ1B>)<.E.%FL,VAVS-!>+%)%0"F54`R7(=/7.
M)Y#(SX?:XN%MK=:_Z'9Q,##N<G6,I)Z+=T_^CTM.V^LW*.>25GI#5J]1-S&-
MY]HP=6!%(I"D566?),T.],[D1$@`'0O;F;!O3N8'Z_OCLO4U\O'BK_"TY)1V
M9L-\I%K,Y@KM)LA!J1L@@\17)[;063YJJR426!("F!NH5;L,!>H`.89VVHR^
M31,UK]I0I..ZX_N+5=*6/5C7751K=&FX1TRKT!%Q8,F1DVJR*S=HD18"L5O:
M7(D*W/9\/';QUSZ3X2[AK!M6,6<>,8T]*O\`$^3^7CFW,^[D9$95E*JZT7H:
M3I/S>UO/Z^V8@IA6/&;4L3KEIV@8YEKOM8[6T31?<`2D*I%Q$:"*@<&$!5*'
M(>F;][3?J<N)87FN7&`1H\Q-:.]M^-&W:3&G[)AS5SS<&8$A6.,W4GK2UQ:*
M9`,4?<=O(8B)1YZ"IS]&3;;BT^M2LHJ2:>S1`;5^WCW36=!MK.,5D'5@K,0Y
MDUE%`8M&\P#4J$LV`3(G55%O((J@/80"@(<<YZRQ+Y+2DO0\O?C\5UPEIJ;)
M35GY<!6<R!F34P<`PCP^7*``;GDSP1^;4$W/'("0.G0,R&,R6!/%Q2Z@.^P1
M,`&36<+&7-R4H=Q3JKB80#T$!$?7D,D$?_)2;C-C4VR4FJBSDG<4U3FYHZ8I
M*(MG,2!W35F8Y!^&5<MQ.!"B(F`I@[@XXR`4RH-DV:YW**9TP.L8PE43[3@?
MNY$#%XY`>G7]^2#<M?>(G1`YE![NP?AYXYZ"/'K]&`=#:7BRC5WU`J2:1@#C
MKW!VB/Q?3Z8!&2C;:0K5_<0H0:\@0P&56>=AC)D#W0`0[11,`!SU]<`[?86T
MBSMO;,D8)RV!-)11!R1,P)'4]OGM`"HE*(\AP`<YBORX6G(R6(JY>4.I]<OA
M[K>1U)XRZ:H4R@5M-Q%.:.IQN';RA-3[AS895`PD$Q3';OI4Z8B`]1+_`(9Y
M2;Y3;[GIX*D$F24RI<8`P!@#`&`,`8`P!@#`&`,`8!!/;?@?KZWV]SM?3]GL
MGCENQPX=.W>P-9+_`"B-B4=D[W"%KK*JI8F40>.2E.N9,J"BX@/NBIW"&64J
M:4T!KF)8_FF:U2/&FD/'#R#9$,(,YB?<S5&L?L%^%)-TG%1<)%&6$A.3F$JP
MB81^,0#)^Q]@=J-^_-"D`%LWT)XRUY0_)`D9395AE6Z(CT]T&D:J5<_;Z@4<
MBD?4&-D\/_*;>AETO+CR;7&D.G3=5WJ#1S).MUN78$4(JK$S]B6B8R6=LC@G
MV&(*:YC%,(@J4Q2CD\DMMP3ZU9J+6NDZFVH^JZ?#TJL-ECNOJR(1.4'+U1-%
M):0D':ZBSV2D%TT"%.NX445.!0`3<`&5;;U8-CY`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@$&_.'5\W,U"I;SU]&$?;0\<I\VQ(AFBD<7]IIK
M9HN2^49`R)%%#C.PW*B9.T>Y9N4H=39ELW';FI=#'=ASA3J=C0KW7=E4NM7V
MI/"/H"TQ3659*E4344;BX1(9S&NP3.<$)&,<F,@X1$0,DJ02F#G/10FKD5-=
M3ARBX2<7NC)EUO:055,(?`F<P<\<\\#Z>GTY<K76AK:04^79N7)QX$$E%C&`
M0^GDPB/H'T8)*VMAHFDYIZY$!.*CA93N'GI[BP\=>H`/`?PXP#>'C^N9A(BT
MY$A%B'*(!Z"8`4$O//3T`?V^N0"9S<XMW3=;GC@Y2FX$/B(8>OKP7UP#.`.`
M\"'/:/ISTXY$1]`ZCZY(-9[CVE7],:YL6PK"55PA$)(-8N+:$!5_/6.57(PK
MT`P;B<AG#J2DUB%[2CW`D!S@`]HY2[-68\I>A:U'Y)*,3._#33]@U9J?ZWV"
MB(;?VU-OMH[:6.8!.C:K$"9D(,A"E*1!O6X=-NS!(H"4BJ:@@(\\YYV[/G-L
M[EN"A!);DMLQ%Q@$%?.+75B<UFG;^UU'"\V/X^3:EK5;MC"5]8]6N$3%V;3T
M2@0_S0R$,B5RFCT,=5L!2"!C=<^/==JXI+:I@R+2NVG'K0[[7EVKVQZE7KO4
MGY)*N6:,;2L2Z`Z7>9LY3*I[#LB*BI4'S4XBDNCW"*2I3%'TSTJE\D%)=3@Q
MC\<W&9LA1RT;MPZI&<&*(^V80$4PX_F.'(B7CZ.>,Y>9D.U7CO0[>!B2N37+
M8P*T2[-"/=)]X@J**@%'N*`=_:;@3#SU^+Z`SR^1.<YN<MSVF'8C!)117SL:
M#B;_`!,Q7[`BHT)._,0KM)1-8[)X#\ID^[WT>3H)N2F$OQ\`!AX`>H9P,J$+
MSXSJIOT/98V<[$%39(BWL?Q#H4E$1";)G(R18=L@TCT@O5]:@R(B4@"W9K0\
M\@L@AR0!%,1$I?0``,YV5C-**^]M'4\9Y6^G-QE",'V1D.O-51E)ERV"2F)1
MN9.'5CE8^2LLS-(H-@,59(Q6TF]=&%1'V>[WC\J<"("80Z9&/84'\MW2'H:V
M9FMSK;?WU/+>;"G8V+:-A`>$AWJB:CQ=9`S9S(I%4[DFYD#&[DV0G`I^!X,8
M>WGITS#DP_K8_%#2WZ[%X7>'ZEWW^AX$;6RU76']G>?-*+(>RVAXAL8!DIR=
M=J`WAH5@V$Q#.G#IXH4!*7DP)@8P<\9?QOC+RR(V;<GQ^IQ?-9V/:QG>:CS>
MVF_\2Z#PXTI,Z4TS&L;L9%WM2ZR,C?=J2Y53NG$A;;"Y4<BU7>JIIK.2P,8*
M#$G<'``@/;T'K]#2:5&ZL^7_`,25F2!@'Y,'<''`"`\@(#U#@0$!Y#J`^N`4
MC6.#-XS^0-ST_(-4DJ+MN:E=IZ-625(WBHY.153+<Z"4SD4$FKR)F3BX:MTS
M*<M5BB'Q'`N=KQV1I\<GKT./Y&QJKD5]3836-LMI(^,A9U*\1`QRMDX1%@['
ML`#`!W2LFU<I*G$>HE*F`<AT,(<YV#DUTJ8%,Z1DK.T3;2^W]F-D#.RJK!7I
M.#@S.T$C@8T<[69097B;-8O!3BFHFKQZ'`<!--56QI-SJ=WH"L2[>J.)FPP4
MG**J+K2;H\C.I/9ETN)UGCDR95'R`.%A[G!S"H4O`FY#K@%?,S-1CNX6"&^8
M0&0:R+D7+8AB@)#F4$W/'_G,(CS].`=Q'JG;*E)W`5,0$>G\!YY]`]<`[V3!
MLX;II<=PK%,4?3@0$./7U^G`.HI]!AT9PST6C?M6*(',8I1,/Q`(]3=1`?V8
M2KL0Y**JR6?C5X^PN^_)"J5QO"M9"@ZI7:7C:[P0[62WP+*5"I%53,`KN)>7
M:@=PD!BF*U14'GIQG'\AE*GPQ>AU_'XVOS3/I6#GCKZYQ3L,YP!@#`&`,`8`
MP!@#`&`,`8`Y#_N^G_+`&`5U:IVEL.:_,7\DM6RMOEW^NZGJRHS-;J"ZB`Q$
M-*OF]$,\?,R%0*N5=P:17$W<H8/ZINF05UKV,AB-D7M?\QJVZL6M,HIKICXU
MQ=M:5`QT?JAO95K6P9*S*9`1!<'AVBIDQ$5!+VB/3+Z<6^HK]U">?.4J6'(<
M<Y('(=/W^GK@'(].H^@8!QR'[?IX_P`>.?\`A@'.`,`8`P!@#`&`,`8`P!@#
M`&`,`8`P!@#`&`,`8`P#@0`P<&`!`?4!Z@/\0_9@%46T*38/"BYV?:E0AY>S
M^+=_F%9O8=+A2?,/]'6R4>'5D+W6XSW"I+TJ;=.BE>LFR93MC`!@^$I>-W&R
MY6GQEK$TLC&4TY1W-XDV10+#"QTG`W.LRT9.M$I&,>,IEF=-[''$!!TD45"J
M@D)@[3`<I3%-R4P`("&=R+4URCL<KVOB]S7]TN591@W8)6*%,=9!4A0))-#]
M`(8HB!BJ\#VB(\_PR2::5Z$%9RQU-5RH)K-`\F743[1E67N"H7M.*8$]T#>Y
M\7IZ\9`,^U_<ZC$3+8RMFA$3@8IA*:1;@82G$>!'^IR(<&_9QD[@E>YW!JYD
MJR:/K]56KIZF*C9!65;E,H1,P%,IW<F(1,JG3DP@`#DN+6Y#=-69/+;MU54Z
MS(VBTWZM14)#M3.WC]2137#Y<HE*4K9NV]UR]<'.;M(FD4QSFXX#*3DK:K/1
M%HQE/2*J85HK5]M\E=@5OR1V_!/:SJJIF7=Z"TW/H$,^>O5T1;CM?8#%1,S1
M5X[)PM"-A**C,O:J(AP4RO#R<F5R7%.J.MCV%"/*7O+-PZ!_[?7-,VCG`&`>
M-5,BR2B2J9%4U4SIJ)*%*=-0ARB4Z:A#\E.0Y1X$!Z"`]<`J@V14ISP=MEBO
MM6B7DQXHW^76E[7`Q#<SA[H"YR[D#R%KCH]LEQ_IA(%``5:M2]S-<P<`!>WO
MW\;,E&/"?X&G=Q8SN*??4V^39<&_@F,VSE&#EA*,R2<1*M':;J,GXU9)-5-Y
M%.RB`+=A52^XD<"K)"/!B\AFCG7W^9T/3>.Q5*7Z:KIT-+&VQ"S\RI`DDDE'
MQ4E7";4Q^%546ZB1%E.T>>Y-,ZI>1#T[@SB3O*3I%U9Z>WCNW;3:?<Z^UQY%
MVICD2[`7``$0,4![R"*@F*?_`)3$,`"4?H$,PW+%NG*6DBT9MMVUK'_8TU*/
METR'37^,>S_E`Z:B@%Z"IR4X%$Q@`!YS`[L(+[U4VK5EI5MUI]35,W)$425;
MJ"5)H<!!5-(IBK.2ASPD=4YN"I&YX.`?SAT].<T;\HRCI[3<MV)>^Y[3!9JR
M0L+%K3<Y)MHV-8$Y5443[S%,3J4B`!R=PX4-P4A"`)A$?3CJ$8]OYI_'957V
M)S+MK&QG?R)*,?\`7\-R=GA;XLV.^6*`\CMVP1HJ!B$2R.D=93!`6<HJ/6QB
MI[)MK13W6POGS%8BD6V.`*M1'W3`0Q4^?68N);Q8T5'/U/FOD?(7<^]]W\F+
M^U>A<-FT<\8`P!@$>?)?QZK?D=K=W4)58T+9HM?Z^U[=&A1+*4VY,DE!B9=L
MNEVN3,?F!*5XW*<I7*')1X,!3%M;F[<N4=RDX*Y'C+8J8IE\OFNKL\TAM:#+
M";>B.4Q%1XDA7;K`^XH@RO-5<B(GD&,J"'<=J0!<HG,)3$*)3@3T6'EQO0XR
M]Z.!EX<K4^<:\#=\_)7"N((OBH1DJDX*)C((@>/6`P!_(DHX.NDIR(\?$).H
M<".;J>M.IIO15Z&JW6U6EOD6](,P49R:CUFC,,9!$`4CTE3>X51</B153-T,
M4R9SIF#Z?7%56G4)UU13EN+6KW4OEY;?K=X?LL[9N\0;'6#L2<'5,L50J1.4
MP2<H*%.7M^@<D&P3*"95(`$1`PAP/(]`_</`#ZX(JJTZG2WB<E8%FBNQ9F=B
M4H&[0'D1X_9P'KW8);IN?C2L-OKR$V'$ZYUK#^U,OQ(N[7.!P8P4."Z+=S8)
MYTF!QCX=@=<HJ'[3J'$0(D0YQ*4=#*RXVDXQ?W&[BXCO24I+[#ZM/&7QTJ/C
M3K..H]=`)&:<F"5N]N<HI!+6^T."F,^DGC@"`N+%!54Z;%N<Q_E6W:3D3=YC
M>>E)SDY/J=^,5&/%;(D/E2PP!@#`&`,`8`P!@#`&`,`X'_NP"JV][AW]Y6[R
MM^B?%VY)ZGUCJ=T>)V[N\L8G)2[RR"J[:.:Q46[UN0ON,'3,Y"G;K(G4$AU3
M+D2]HJV2BBJO5E=6]-CVR>#OD5K)L[M>EO-+:<E?&[<[@L+M!%M9:5:7:8BI
M]7R#.1>2)(A!T/)2J$26%,1*/3CN!S3T:T)HT:5\&[S<=B>?_D;9-B54E*V`
M74,)7[O6$7!736,L]4DJ/7986+@IE"K1SYS'"Y;B!U`]I8H`<X`!S)1BE5;L
MJG]QX=_7[:]*_,AG(S1U6C[/M/8OCO7*%55)E<R,#5%WLVYFW=RG@!NX*O&0
M;*#4$R9^PASG(`B81!,]8THZ[!^\D*X\#-O6@G]QWOS<WHYV0H"+A*5JAV]:
MJ,.Z_G.V8U!@\;LGC!$_PE]P4C'*'(@41X">4:[:%J/U.-(;RWCIS?;7Q1\J
MYR/N*UPCW<KI#=*#9E$FNK9@*1#P$[',R^PE-+&!4"^X8JY5TRI#[Y5DEA.*
M:Y(5IHSOMU;1V;H/S'TO,S%GD7GCGO1FEK"3A9)TV&%I>S1,X5BIAB`I?,L?
MK0I&@*&.<$!3,Y'H)>B,4XOU(;H^Q/BS66%IU=G+79'Z$5`UV*?34Q(.3@1!
MG'1S8[IVN<P\!\"28\!ZF'@`ZCE4JNA+VJ0D\#K=MW<58O\`Y![+GY4];VO<
MI%SJ*B+N2&BJ50(5X[BT1:()MVQS.)-\W.`J*@90R:`'`0!4>9DE%T03JB?.
M5)&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#\*))K$.DJF15)0ATU
M$U"E.FHFH42G(<A@$IR'*/`@(<"&`4@^;WY,&L-^-'UFTA+O]2W0AWLBE7HJ
M;FH6L2$F[]LRJD8\CW9E:Q[YO<.HW%N[CUCGX]E$.39LVLFY;T3T,%S'MS6V
MI\T>]?RGO*K2JQXZYN=QK-U#`JA9"3DK,U\4D#J`HH27JB\C%$*J'42+G:JF
M+U%,`#.G#R"<:'/N8,JU3T(IPO@W(FD#OI.]62,D2OS.04_O1T5?DHC_`%#I
M.RJE]T>>O<7GCZ<SK(LM>Y&%V;J?M=#-T_$Z_*6A#ZNWO>8QB``1<[1RTGGB
MQ!2$I$VX`F)DC=W3@$S`(?1SB5^Q3605F[Z,F_IC\J7R/W8]:KU\FUK5&MBI
MLW5MOCQU0X`S=50%>XBT@O#%>)D`1/\`]&W>F#T[!'H.K//MP5(+[C8AA.3Y
M2J?2#X8?E,ZF\<VL/8=DNS;5O4>NWEHYE).)1W3:M*@F7O4:,I-ZX/8WK<_(
M$<.TTVY0^)-JF;@V<V[D7+SJWH;]NS"VM-RW$"@'H'IZ?N^C_+C,!F.<`8`P
M!@'A<((ND%FSE%)PW<)*(+MUTRJH+HJD%-5%9%0#)JI*$,(&*8!`P#P./H"L
M?;W@/)0B=BL'BI8(ZF#8#N7MGTG<4UYC5-N=N5A465AEG"SB0UU(G!=8WN,2
MF1.<Q0`J12!QCO6HWX.$^J-K$S<C"FKF.Z-.M&?/W+:<\^?%3S"6O]^I,JIX
M[R]:=P+&,,+FUR5$5D)6,E7*S:ZPC.4BK9#-EXP2D%RJSD?84*4Q#BD8YM>Y
M@6)6E&->:/3V/\G^6[PRXI6^._2O["T>.\F=/R\"F138]>3D4FX>XV?G<Q;I
M,_`=Q#DD6C<0YY]<QSQ+BC2E3;M^2\;)\ODBG^/\"--]\D*FBY6;P4F6PNS&
M$J*4.19\)C<CVE`4$C<@8!_Y1YSCY&%FR=+=N3B=&WY;Q5N/&Y>BOV_P/4UY
MJ?RQW^[,XU[J>?:0QU.`LEV`*;6VX'$0%<%YQ)!W*`F'409I.!Y`0XYZ8QO"
M7[KYYD^"](G/\A_E6%;B[?C[;N7O^3K%%M_CA^7+3=:R</L'=$T7<&SXI5N_
MABJM5HZBTQXF4ARA"0'S)DYI\U<=XD?/2<_$`E1(8H&ST./C6<6'"PJ=SQF5
MG96=<^3*E6?[E]"RP``/3_;C,YJG.`,`8`P!@&D]X^/>J_(BLHUC9]>-)I1[
MKZP@9N.>N(>S5J3]HZ)9*OSK$Z;Q@X!-0>2\G14Z=Z9N`XO"<H.L7J5E",U2
M6I6=L#Q^\Q-2)K1\0W8^46MV2:2D<_;N8NG[7BFI#"51G(13I08VSJ(I]H$5
M;JBX6`HB)`$>,Z-GR5R.ES6*.=>\;;E]UK2;(76;<D(A.PZDNK;-0V6,=@D^
M)>*-,1#Q)C\?S+#NDXEPV`AU`)RJ0>2B'3@!$<Z-O.L3ZTB<R6!D6YMZR?8@
MOYK+L+5=]?;8I]P8W238"G&V!*,D$G3U5LW[A:O3H"*9B@1`X)=H$#M`@?3F
M;^IL;\E0JL>^]X.IV=8=35L58-*M6;79Y1;VNV-K=<EYMX98X!P0Q(]FN4G(
M@/41``X_CF&YF8T=:U9DAAY,GM1=RQ+4OY;GD7MM^S>[2*VT?1S)IJN"/%X^
MQWZ30%0G>S:0S!T+*".L@!@%5VN"J(B`^R?TSG7O(N4>-I41T+/CE%\KKJR\
M71GCSJCQTJ@U'5E:+#M'"X/):5>.%9.PV"0]I)$S^:F70F<NE#%1#M2+[;9+
MK[21`$0'FRG*3JV=*,8Q5(K0W9E2PP!@#`&`,`8`P!@#`&`,`8!X7!53HJE0
M/[:QDU"I*"'()J&3,"9S!P/(%.(#DH%8OY6[U@RUSO*E2"Z">PZSY&;)5O$>
ML<A9<%7RS!NPDG:!Q*Z^5='CETDU#%`HG04*'4!R]S=/H5C^\L_Y`0]0]?H$
M/4!_X\YC:98J@T))04G^:9Y<K0!FYV[;5E:C9)1L)!(>P19M>LIL#&3,)160
M>HBDKS\154Q`>!`0R\ME]"GYC(&D]7(;\V"?9SCEFTD;'XO0L-5C.U443.I@
MMD"4<1[,RIB"H]<Q,>N<J9.3G(D?@.`'(2?%OH/SEGX<<=/3*51<JV\^GD7+
M[U\%J5!H_-;/#?4);&?RB/O/XRB1K]@6PNG!TNY=M'.7*":@B(`F8K)0PB'M
MCF6%>,GTH5DJDJ_,/12?D/X^W[7C9JV6M(QQY^@NW`@FI&7:#*=W"+M77:8S
M0[W^HR44`!X1='#]^5BZ/L3)::;E9M_\E+#Y6>-OC_XVU1<K3<>]K(KK#;2#
MMQW2=4C=5+LU+Q/2K5M[[UDVL7R!')152X.A\P3CD@Y9+BW)]"-U0NHI-.K^
MOJC7*/5(]&*K=4AV,%"L$"`1-NPCVY&Z)>`XY4/V"8YAZF.(B/4<HW5U9;8R
MG(`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8!P(<]/X_[_`./\
M<C7H#6<]I73MI=*/K-JC6UA?+"(JOIJCUF3>JB(\B*CIY&++G$1'D>39;D_4
MBB/9KFH=44]R1[4M8Z^K#U/GL>U^F5R'>%Y`0'AU'QK=<.0'C^;TQ5BB-B<?
M[?LR"1@#`&`,`8`P!@#`.!`!#@>H"'`@/4!`?7D!]<`UC.Z2TS:'2KZR:EUI
M/OES"99[,T6KR3Q4P\B)E'3R+67.(B(\\F')JQ2A[U:U+JNF.2O*AK2@55X7
MD`=URG5V%=``@8!#YF-CFRW4##_S?3BK&^YL#C_CS_M_#(!S@#`&`,`8`P!@
M#``]?VA_#`.IF8&#L;)2,L,-%3T:KS[L?,QS.48J<@)?ZC1\BN@?X1$.I?0<
M*J!K`/'/Q]!;Y@-&:@!?GGW`UK3@-S^W_P#3<<\CEN4O4K1>AL^&@8.NLB1U
M?AHJ"CD__EL(:.9Q;)/_`.!JQ100+_@7*UJ30[;!(P!@#`&`,`8`P!@#`&`,
M`8`P!D-I;@XZ#](?[LD497;O#Q2VA"[9D/)?Q$N$)1=KSD>9AL*EV9J52@[.
M:H)]Z"KMLW2(FRGUUR`*CA40!13A4%$5?<.K9235);+]Q72J:W?[S#T)'\TW
M991J$K5]$Z`CG:"K>4V1&OE;=,MD3$[5CU^&0M,V1*15+W`D<Z903,8#`<@@
M!@E\$JK<4D]#L/%'PJL_C7Y+[0O"$P:P:WLNN(NOQ,]/3AY2\SMK5>UR8L\W
M8TC-TRIGDYEH\5*8#FX*8A>O\PPY-K78A))[GI;X\&;1O3RDL6VE[0XH\,VU
M'`QFL[K6)EPVMU2VU7I@SN+FU(U$J'S<,BR=+D5("Z9E`/P4Q#<&`I4T>P>Z
M:V9Z;RP?FPU<5:FSHWCSLE-N!6K39WU@:$%ZF4I0"0>P#JUPQT7/`\G(#,"]
MP#P!@ZC/V5ZH)MOL;6\;?$FUTW9$UY&>0][)M+R"L;!:*;.XU)5M3:%!.T6J
M*T/5F*Y$Q(M[2!DA633;I$144(1,14454ARZ+8N3U$>@_P`/3Z<J"!^H?"RK
M:M\L=Q^0K1O&_5MR8,G%&C2")W5<L-E.^<;->]@I$3;)R3L$OE0((@1%TNGT
M#C+.58I=2$M6R>'(?MRI)SSD<E2M=`,D#`&`,`8`P!@#`&`,`8`P!@#`&`,`
M8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@
M#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#3&Z;C:J=$U-S58M:07E=@4Z#?BDX
MAD`".E)QHT=,A^N%"$!2425,D11/XD1'N$Q`ZYU_"XF+F9$X9<^%N-BY):-Z
MQ@VMNYQ?-YN9A8]N>$JW97[<>FTI)-:I[KKT,9E_(F!8SEBA(J)3EE:6^+%V
M\SBW5"NN&4L6-92SF(@F$_+LG-D?LF;],%#)^RU,L84B+&4*<I<MGP-R=B-Z
M[.<'=CRMTMRFI*KC636EM-KNZ:TVKK7O/6[5^5FS;A+X6E<K=C!ITY-03UN-
M)]M=*G?-MVQ5D-!LM>04I=Y>>IL1?B,DUF4`SB*O.N'+.)=S\E+JD(R>OWC%
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M%=MGR0G7$R*B`@<%$R]AAS!:\)._>4K%VT\6=B=U3E6-5;]U51M25-M:Z4>I
MFGYR-BTU=M7/ZF%^%IP5'1W/926BE%Z:Z4ZK0[-QO*.@%+6PO%8G:S.U2`AK
M4I",S,[.XFX2QS3NN0/U"K#*G*]F'T^T%F9F8$SD7.3@QDSE4&C\/*]\4L*Y
M&]:G.4>33@XRC'E*J==%'5/JNB>A?^\QLJZL^$K-ZU",G%-3Y*4N,>+5*NNC
M71]:'F7VM*L7K.!ME'FZ1)6EG/A3'ZSZ%L$:\D86$>3:L9*.89TZ3A9@&#,Z
MR2*P';N/:.1-8YR]HEXVPVKF)>5Z,''Y%Q<6DY*-8UKRC5T;TI6M!+RF1%?'
MEV96)W(R=M\E)-J+E25*<9=M4]JF'ZWW-8K%2=?M8ZM26Q;XXUI1+?>731Y`
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M["N80$>TB'[AQ(1<E%O5&:B+U8$TW+=`XB0A5P`H9[/B8VXPR(RMW\6Y&_QK
MRB_TX<FY):J2JG%5:?70P7O+SN.=B[&YCY5J=GE1QE_,E1<6]&GJFZ5[5/S)
M^2E78.9UPSC49*LU=],1TY-$M]+921UH!99O,K0-5?SJ$W-LXY=LJ01[45G!
MDA^52<=Q!,M?X_?N<8S<HY=Q1<(\)M-2VY32I%_@UUDT3=_R/&@I3BE+'MR:
MFW.*E5>YP@WRFD_I7HF9Q%[793UW+5("'5E6(1<1++SQ)F#9C\A.QJ<O&RS"
M!?O6LU+5\[5=--1XV3.4CHXI`0PD5,32N>.E9Q%DW;E+CDTH<6TN+<6G):*6
MFD7TUKL;MKR,+V:\:U;K:48MSY)-\ER3C%ZN.NLEUTH;=SG'7&`,`8`P!@#`
M&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8
M`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@&(7.HM;DQB63
MMXY9DB+/7+0D=J5(QUG-;DT)1NU5!8IR@W<J(`4XAP8"CT$!S:Q,R>#<E=A%
M2E*W.%'_`.\7%O\`!.IIYV''-LJU*3AQN0G5>L)*2_;0UXZT\Y;3%QDJA<'-
M7;WV2--SS-6O0T^=E/+Q[2+>S56>2($-"O'K9BD=0BQ'K?YDONE2`3'`V[;\
MK%6K4,FRKKLJD?OE&JK7C-+W)-]*.FG<Y]SP];EV[C7?B=YUE]D9/E3W0;]K
MIZU5=?K[BVIE6$U%VFJV^7B+0TJ$71YF4EVC2S(V^#A5G#N*7LK)88[WYQB]
M>.52/&ZC<W_5K%,4Q#%*2B\G&5N5G*LPG8=UW%&#<.$I:/B]?MI3[779&1^*
M^.Y&]BWIQR/B5MRFE/FEJN2T^[NJ::'M-M7+JSM%LU@N<]8YJD35MFT%WC2(
M:-G9K9`N*^K&$9L&2!6$3%-5^YL0ICJ]X?U%%.1S&_(*-F_CV;4(6KT8)TJV
MN$N2=6]WUK^!DCXUN_8R+]Z=R]9E-K9)\X\6FDMHK:G4ZR=TA#SEG?V=:<ED
M',AL77&QCM44F0MTW^MXU*,81Q!41%06,DDD!ES"/N%,/P"`9>QY:]8LJQ&*
M<59NVZ]KN[^JZ$7O$V;]]WY2DI.]:N4[VME]'74]NXZ8@[K8;#89*8G6*\_1
M86D!]3KMV3F'-7K4[N$/98=\9NNLWG8Z9<$42,<#I%,@0>P>H#7%\I>Q+5NS
M;C%QA=<U55Y<HJ$HR76+6Z[LC*\38R[MR]=E).Y:4'33CQDY*4?_`&3I0\9M
M5RTQ-04S=KY)V8U60F"UY@TAHVOQR<E-Q#F!<S\RW:&=?7$NUC':I&P@*#=`
MRZA@2Y,427_N-JU:E#%LQAS:Y/E*3I%\N*VHFUKNWH0_&W;UV,\J]*Y\<7Q7
M&,55KCR>_)I/39)G2UW1RM%1A/["N\E`O(^D5BCS9WL)$S4;:6U2CTXR"GY&
M.,#%1O96#(@HD717*B*`@0Z)P(02Y+OF%E1<,VU"Y;^64XZN+AR=9135?M;U
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MYN[5:*+"*)R`!`+HKS"DXSR;7RY,(I<N<E%\52/**WHJ+1JJ5&;S\(HJY;Q[
MO"Q<FY4X1<ER?*2C)ZI/7=.G34[2P:G&RW*G664LK@T=1;`WLM=B4(2*2D6;
M]&&>0JC$;0!!DC0#Y%\=5RV[`.NJ``97VP`F8K/DU8Q+N/"W^I=CQE+D]552
M]FU531]$9[WB_FS+63.Y^G:FI1BHQT:37N]U'6K6U=3<F<PZXP!@#`&`,`8`
MP!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`
A&`,`8`P!@#`&`,`8`P!@#`&`,`8`P!@#`&`,`8`P#__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
